Phase Ib dose de-escalating trial of NB-1001 in patients with short bowel syndrome

Trial Profile

Phase Ib dose de-escalating trial of NB-1001 in patients with short bowel syndrome

Planning
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs NB 1001 (Primary)
  • Indications Short bowel syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 According to a Naia Limited media release, Dr. Pimentel will be principal investigator for this trial.
    • 30 Nov 2016 According to a Naia Limited, the company has submitted an investigational New Drug (IND) application to the US FDA to initiate this trial for NB 1001.
    • 26 Jan 2016 According to a Naia Limited, the company plans to file an IND in the second quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top